This is a Phase 1/2 single-blind study to evaluate the safety, tolerability, and immunogenicity of licensed BNT162b2 (Omi XBB.1.5) and RIV administered together as a single injection (referred to as BNT162b2 [Omi XBB.1.5]/RIV) in healthy adults 50 years of age or older.
The George Washington University Vaccine Research Unit is seeking volunteers who are:
- Male or female participants aged 50 years of older
- Good general health as determined by medical history, physical examination (only if required), and clinical judgment of the investigator
- Have NOT received a COVID vaccine within the last 6 months
- Have NOT received a flu vaccine within the last 6 months
Interested? Fill out our interest survey for more information.